Ana Maria Alvarez, MD
Articles
Uracil/Tegafur Plus Oral Calcium Folinate in Advanced Breast Cancer
Eduardo Richardet, MD, PhD;Cecilia Pedraza, MD;Elizabeth Mickiewicz, MD;Guillermo Lerzo, MD;Federico Coppola, MD;Alicia Elli, MD;Graciela Uranga, MD;Silvia Jovtis, MD;Mario Bruno, MD;Monica Ventriglia, MD;Maria Andrea Cuevas, MD;Ana Maria Alvarez, MD;Luis Alberto Suarez, MD;Luis Fein, MD
July 1st 1999Uracil and tegafur (in a molar ratio of 4:1 [UFT]) has proven activity against breast cancer and is delivered in an easy-to-administer oral formulation. Orzel, which combines UFT with the oral biomodulator, calcium folinate, may
Latest Updated Articles
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Published: April 17th 2012 | Updated: January 19th 2025
A 67-Year-Old Male Cancer Patient Presents With a Painful Erythema Involving the Face, Arms, and Chest
Published: March 1st 2018 | Updated: January 19th 2025
45-Year-Old Female With Gross Hematuria Post Partial Nephrectomy
